News and Trends 9 Aug 2017 Danish Diabetes Biotech Rakes in $75M on NASDAQ in American IPO After announcing its intentions last month, Zealand Pharma has gone public in the US to fund its diabetes clinical trials. Zealand Pharma, a Glostrup-based biotech focused on peptide development for diabetes, has been public on the Danish Aktieselskabet exchange since 2011, and since then its share price has risen by 50%. After filing for an American […] August 9, 2017 - 2 minutesmins - By Evelyn Warner Share WhatsApp Twitter Linkedin Email
News and Trends 20 Jul 2017 Update: Danish Psoriasis Drug Gets EU Approval Despite Suicide Links Update (20/07/2017): The European Commision has granted LEO Pharma marketing authorization for Kyntheum (brodalumab), making it the first biologic drug that targets IL-17a. Published 22/05/2017 The EMA has taken up a positive opinion for Leo Pharma’s psoriasis drug brodalumab, even though the drug has been associated with suicidal behavior. Brodalumab, a fully human antibody targeting the […] July 20, 2017 - 3 minutesmins - By Melanie De Almeida Share WhatsApp Twitter Linkedin Email
Interview 13 Jul 2017 Meet Denmark’s Youngest Professor and Serial Synbio Entrepreneur Philip sat down to chat with Professor and serial entrepreneur Morten Sommer about his career in the second Labiotech Hangout. At 35, Morten Sommer is not only the youngest full professor ever in Denmark but also the entrepreneur behind a number of synbio-based companies. For Labiotech’s second Hangout on June 29th, Philip probed his thoughts […] July 13, 2017 - 4 minutesmins - By Evelyn Warner Share WhatsApp Twitter Linkedin Email
News and Trends 10 Jul 2017 Danish Diabetes Biotech Shoots for a €75M IPO in the US Nasdaq Zealand Pharma, known for its partnership with Sanofi to boost the insulin blockbuster Lantus, is aiming high in an IPO on the US Nasdaq. Zealand Pharma has announced it has already filed for an IPO at the Nasdaq Global Select Market, an exclusive listing for large cap companies. Currently listed on the Nasdaq Copenhagen, Zealand Pharma […] July 10, 2017 - 1 minutemin - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
Startup Scout 30 Jun 2017 This Danish Biotech Thinks it Can Tackle the Obesity Epidemic Apart from boasting big players in the space of metabolic diseases including Novo Nordisk and Zealand Pharma, Copenhagen is a hotspot for research on obesity and diabetes. This week we had a look at Copenhagen’s latest addition to the field, Antag Therapeutics. Mission: Antag Therapeutics is working on new treatments for the growing number of patients with obesity. […] June 30, 2017 - 2 minutesmins - By Melanie De Almeida Share WhatsApp Twitter Linkedin Email
News and Trends 28 Jun 2017 Danish Biotech Reports Positive Phase II data for a Common Cold Vaccine Bavarian Nordic has announced positive Phase II results for its universal vaccine against the common cold virus, RSV, which can be deadly for the elderly. The respiratory syncytial virus (RSV) is one of the perpetrators behind the common cold. For most, the virus just leads to a few uncomfortable days or weeks. But for children […] June 28, 2017 - 2 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
More News! 20 Jun 2017 Belgian Llama Antibody Developer gets Second Preclinical Milestone from Danish Pharma argenx’s 2015 deal with Leo Pharma for anti-inflammatory antibodies continues to pay off, though it hasn’t been disclosed by how much exactly. Two years ago, Ghent-based argenx and Danish Leo Pharma teamed up to develop antibodies to counter inflammatory diseases in a deal totalling €105M. argenx just received its second preclinical milestone for granting Leo access to […] June 20, 2017 - 1 minutemin - By Evelyn Warner Share WhatsApp Twitter Linkedin Email
News and Trends 6 Jun 2017 French Biotech Strikes Deal with Novo Nordisk for New Cancer Drug Novo Nordisk has handed over its anti-cancer antibody to Innate Pharma in a new deal that could earn the diabetes specialist up to €370M in milestones. The immuno-oncology biotech Innate Pharma has in-licensed a new clinical-stage antibody candidate from Novo Nordisk to reinforce its position in the crowded space. In exchange for its anti-C5aR antibody, IPH5401, […] June 6, 2017 - 2 minutesmins - By Melanie De Almeida Share WhatsApp Twitter Linkedin Email
News and Trends 17 May 2017 Danish Biotech Targeting Ion Channels Completes Private Placement The biotech company Saniona has announced the issue of new shares to Swedish and international investors, raising a total of €3.6M. Saniona, a Danish biotech listed on the Nasdaq First North Premier, just completed a private placement that raised €3.6M (SEK 35M) before issue costs. The funds are intended to provide the company with more flexibility […] May 17, 2017 - 1 minutemin - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
News and Trends 10 Apr 2017 Swiss-Danish Collaboration will use Synbio to Produce a B Vitamin Two startups in the fields of synthetic biology, Biosyntia and FGen, have struck a partnership to identify promising microbial strains. The objective is to find a strain that enables bioproduction of a B vitamin. The driving force of this new partnership between Biosyntia, Denmark, and ETH Zurich, and brands itself as a CRO for biologics […] April 10, 2017 - 2 minutesmins - By Denise Neves Gameiro Share WhatsApp Twitter Linkedin Email
More News! 1 Apr 2017 Will we Rely on Biomining to Build the Tech Devices of the Future? The Danish artist Jacob Remin explores how biotech might be essential if we want to keep building smartphones and laptops. Computers, tablets, phones, television screens… we take our electronic devices for granted. However, the rapidly increasing demand might not be possible to meet because of rare earth elements, a series of rare metals that are […] April 1, 2017 - 3 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
News and Trends 20 Mar 2017 Will BMS Take Over a Danish Biotech in a Massive €400M Deal? Galecto Biotech has presented positive data from a Phase II study with its pulmonary fibrosis candidate, giving BMS the option of take over the biotech. In 2014, Denmark’s Galecto Biotech has signed an option agreement with US-based pharma Bristol-Myers Squibb (BMS) for its lead asset TD139, which is under development for the treatment of pulmonary […] March 20, 2017 - 3 minutesmins - By Melanie De Almeida Share WhatsApp Twitter Linkedin Email